ATON: Loss Stabilization and Commercial Deployment

The ATON Group has published its half-year results for 2026, marking a milestone in its transformation into an integrated life sciences platform. Revenue amounted to €223,000, down from €287,000 in 2025. Net losses remained stable at €503,000, despite a 50% reduction in personnel costs. The financial situation remains fragile, with cash reserves of €25,000, compared to €455,000 at the end of 2025.

The Group's equity was strengthened through the conversion of bonds into shares, totaling €1.0 million. However, cash flow remains tight, requiring additional financing to support the commercial rollout phase of its subsidiaries.

Inoviem Scientific and PIMS Technology are continuing their expansion, notably through strategic partnerships and financial support. Bcell Design is developing the commercialization of antibodies for diagnostics. The coming months will be crucial in converting this commercial potential into concrete revenues.